| Literature DB >> 26553142 |
Charlotte J J van Asch1, Birgitta K Velthuis2, Gabriël J E Rinkel3, Ale Algra4, Gérard A P de Kort2, Theo D Witkamp2, Johanna C M de Ridder3, Koen M van Nieuwenhuizen3, Frank-Erik de Leeuw5, Wouter J Schonewille6, Paul L M de Kort7, Diederik W Dippel8, Theodora W M Raaymakers9, Jeannette Hofmeijer10, Marieke J H Wermer11, Henk Kerkhoff12, Korné Jellema13, Irene M Bronner14, Michel J M Remmers15, Henri Paul Bienfait16, Ron J G M Witjes17, Jacoba P Greving18, Catharina J M Klijn19.
Abstract
STUDY QUESTION: What are the diagnostic yield and accuracy of early computed tomography (CT) angiography followed by magnetic resonance imaging/angiography (MRI/MRA) and digital subtraction angiography (DSA) in patients with non-traumatic intracerebral haemorrhage?Entities:
Mesh:
Year: 2015 PMID: 26553142 PMCID: PMC4637845 DOI: 10.1136/bmj.h5762
Source DB: PubMed Journal: BMJ ISSN: 0959-8138
Causes of intracerebral haemorrhage in participants
| Causes | No (%) of patients (n=298) |
|---|---|
| Macrovascular: | |
| Arteriovenous malformation | 34 (11) |
| Dural arteriovenous malformation | 13 (4) |
| Cavernoma | 10 (3) |
| Cerebral venous sinus thrombosis | 4 (1) |
| Aneurysm | 7 (2) |
| Developmental venous anomaly* | 1 (0.3) |
| Subtotal | 69 (23) |
| Other: | |
| Probable cerebral amyloid angiopathy27 | 18 (6) |
| Hypertensive vasculopathy† | 36 (12) |
| Neoplasm | 3 (1) |
| Cocaine use | 1 (0.3) |
| Haemorrhagic infarction | 2 (0.7) |
| Unknown‡ | 169 (57) |
| Subtotal | 229 (77) |
*Partially thrombosed large developmental venous anomaly without evidence of adjacent cavernoma.
†Intracerebral haemorrhage in basal ganglia, thalamus, or posterior fossa in presence of hypertension.
‡In 30 of these patients, lobar haemorrhage in the presence of hypertension was observed.
Prevalences and prevalence ratios of a macrovascular cause in 298 patients with intracerebral haemorrhage according to presence or absence of clinical and radiological characteristics. Values are numbers (percentages) unless stated otherwise
| Characteristics | Characteristic present | Characteristic absent | Prevalence ratio (95% CI) |
|---|---|---|---|
| Age <50 years | 42/112 (37.5) | 27/186 (14.5) | 2.58 (1.69 to 3.94) |
| Male sex | 45/185 (24.3) | 24/113 (21.2) | 1.15 (0.74 to 1.77) |
| Glasgow coma score on admission: | |||
| 3-11 | 10/28 (35.7) | 34/165 (20.6)* | 1.73 (0.97 to 3.10) |
| 12-14 | 12/55 (21.8) | 34/165 (20.6) | 1.06 (0.59 to 1.90) |
| Verbal score not applicable (aphasia) | 13/50 (24.0) | 34/165 (20.6) | 1.26 (0.72 to 2.20) |
| Alcohol intake†: | |||
| None | 24/114 (21.1) | 41/144 (28.5)‡ | 0.74 (0.48 to 1.15) |
| High (≥4/day) | 4/36 (11.1) | 41/144 (28.5) | 0.39 (0.15 to 1.02) |
| Current smoking | 20/72 (27.8) | 49/226 (21.7) | 1.28 (0.82 to 2.00) |
| Drug misuse before ICH§ | 5/12 (41.7) | 64/283 (22.6) | 1.84 (0.91 to 3.73) |
| Hypertension | 16/95 (16.8) | 53/203 (26.1) | 0.65 (0.39 to 1.07) |
| Diabetes mellitus¶ | 1/18 (5.6) | 68/279 (24.6) | 0.23 (0.03 to 1.55) |
| Hypercholesterolemia** | 5/26 (19.2) | 37/176 (21.0) | 0.91 (0.40 to 2.12) |
| History of CVD† | 2/12 (16.7) | 67/282 (23.8) | 0.70 (0.19 to 2.53) |
| Family history of CVD†† | 12/55 (21.8) | 51/228 (22.4) | 0.98 (0.56 to 1.70) |
| Oral anticoagulants§ | 0/5 (0.0) | 69/291 (23.7) | P=0.59‡‡ |
| Daily antiplatelet use | 3/31 (9.7) | 68/267 (25.5) | 0.38 (0.13 to 1.14) |
| Non-contrast CT assessment: | |||
| ICH location: | |||
| Basal ganglia or thalamus | 5/85 (5.9) | 49/178 (27.5)§§ | 0.21 (0.09 to 0.51) |
| Posterior fossa | 15/35 (42.9) | 49/178 (27.5) | 1.56 (0.99 to 2.44) |
| ICH volume >11 mL (median) | 34/148 (23.0) | 35/150 (23.3) | 0.98 (0.65 to 1.49) |
| Subarachnoid haemorrhage | 21/56 (37.5) | 48/242 (19.8) | 1.89 (1.24 to 2.88) |
| Extension to frontal operculum | 6/12 (50.0) | 63/286 (22.0) | 2.27 (1.24 to 4.16) |
| Intraventricular extension | 23/71 (32.4) | 46/227 (20.3) | 1.60 (1.05 to 2.44) |
| Mass effect | 45/191 (23.6) | 24/107 (22.4) | 1.05 (0.68 to 1.62) |
| Oedema | 39/192 (20.3) | 30/107 (28.0) | 0.72 (0.48 to 1.10) |
| Haematoma density, homogeneous | 55/239 (23.0) | 14/59 (23.7) | 0.97 (0.58 to 1.62) |
| White matter lesions | 4/113 (3.5) | 65/185 (35.1) | 0.10 (0.04 to 0.27) |
| Hypodensity in basal ganglia, thalamus or posterior fossa | 1/37 (2.7) | 68/261 (26.1) | 0.10 (0.01 to 0.72) |
| Small vessel disease¶¶ | 4/120 (3.3) | 65/178 (36.5) | 0.09 (0.03 to 0.24) |
| Enlarged vessels along ICH margins | 11/13 (84.6) | 58/285 (20.4) | 4.16 (3.00 to 5.76) |
| Calcifications along ICH margins | 7/7 (100.0) | 62/291 (21.3) | 4.69 (3.76 to 5.85) |
| Hyperattenuation within dural venous sinus or cortical vein | 6/10 (60.0) | 63/288 (21.9) | 2.74 (1.58 to 4.76) |
| MRI assessment: | |||
| Microbleeds*** | 0/63 (0.0) | 40/163 (24.5) | P<0.01‡‡ |
| Previous ICH*** | 0/30 (0.0) | 40/196 (20.4) | P<0.01‡‡ |
| White matter lesions††† | 9/147 (6.1) | 34/109 (31.2) | 0.20 (0.10 to 0.39) |
| Previous infarct††† | 1/70 (1.4) | 42/186 (22.6) | 0.06 (0.01 to 0.45) |
ICH=intracerebral haemorrhage; CVD=cardiovascular disease; CT=computed tomography; MRI=magnetic resonance imaging.
*15 was taken as reference.
†Missing values for four patients.
‡Sporadic or moderate was taken as reference.
§Missing values for three patients.
¶Missing values for one patient.
**Total cholesterol concentration was available for 202 patients, cut-off value 5.6 mmol/L.
††Missing values for 15 patients.
‡‡P value Fisher’s exact test.
§§Lobar was taken as reference.
¶¶Defined as presence of white matter lesions, or an ischaemic lesion in basal ganglia, thalamus, or posterior fossa.
***Assessment possible for 226 patients.
†††Assessment possible for 256 patients.

Flow chart of angiographic examinations carried out between July 2008 and July 2014
Results of assessment of computed tomography angiography (CTA), and of additional magnetic resonance imaging/magnetic resonance angiography (MRI/MRA) and digital subtraction angiography (DSA)
| Test results | Reference standard* | Accuracy†, % (95% CI) | Accuracy‡, % (95% CI) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Positive | Negative | Sensitivity | Specificity | PPV | NPV | Sensitivity | Specificity | PPV | NPV | |||
| CTA (n=291): | ||||||||||||
| CTA positive result | 47 | 12 | 74 (62 to 84) | — | — | — | 68 (56 to 79) | — | — | — | ||
| CTA negative result | 18 | 202 | — | 91 (86 to 94) | — | — | — | 95 (91 to 97) | — | — | ||
| CTA inconclusive result | 4 | 8 | — | — | 72 (60 to 82) | 92 (88 to 95) | — | — | 80 (67 to 89) | 91 (86 to 94) | ||
| CTA negative result: | ||||||||||||
| MRI/MRA positive result | 4 | 2 | 32 (13 to 57) | — | — | — | 21 (6 to 46) | — | — | — | ||
| MRI/MRA negative result | 13 | 184 | — | 94 (90 to 97) | — | — | — | 99 (96 to 100) | — | — | ||
| MRI/MRA inconclusive result | 2 | 9 | — | — | 35 (14 to 62) | 93 (89 to 96) | — | — | 67 (23 to 95) | 93 (88 to 96) | ||
| CTA negative result (n=103§): | ||||||||||||
| DSA positive result | 17 | 0 | 100 (80 to 100) | — | — | — | NA | — | — | — | ||
| DSA negative result | 0 | 86 | — | 100 (96 to 100) | — | — | — | NA | — | — | ||
| DSA inconclusive result | 0 | 0 | — | — | 100 (80 to 100) | 100 (96 to 100) | — | — | NA | NA | ||
| CTA+MRI/MRA negative result (n=97)¶: | ||||||||||||
| DSA positive result | 13 | 0 | 100 (75 to 100) | — | — | — | NA | — | — | — | ||
| DSA negative result | 0 | 84 | — | 100 (96 to 100) | — | — | — | NA | — | — | ||
| DSA inconclusive result | 0 | 0 | — | — | 100 (75 to 100) | 100 (96 to 100) | — | — | NA | NA | ||
PPV=positive predictive value; NP=negative predictive value; NA=not applicable.
*Reference standard was best available evidence from all findings during follow-up.
†Inconclusive result regarded as positive outcome.
‡Inconclusive result regarded as negative outcome.
§Only patients with negative or inconclusive CTA results included in these calculations.
¶Only patients with negative or inconclusive CTA and MRI/MRA results included in these calculations.
Results of assessment of computed tomography angiography (CTA), of the combination of CTA and magnetic resonance imaging/magnetic resonance angiography (MRI/MRA), and of the combination of CTA, MRI/MRA, and digital subtraction angiography (DSA)
| Test results | Reference standard* | Accuracy†,% (95%CI) | Accuracy‡, % (95%CI) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Positive | Negative | Sensitivity | Specificity | PPV | NPV | Sensitivity | Specificity | PPV | NPV | |||
| CTA (n=291): | ||||||||||||
| Test result positive | 47 | 12 | 74 (62 to 84) | — | — | — | 68 (56 to 79) | — | — | — | ||
| Test result negative | 18 | 202 | — | 91 (86 to 94) | — | — | — | 95 (91 to 97) | — | — | ||
| Test result inconclusive | 4 | 8 | — | — | 72 (60 to 82) | 92 (88 to 95) | — | — | 80 (67 to 89) | 91 (86 to 94) | ||
| CTA+MRI/MRA (n=273): | ||||||||||||
| Test results positive | 51 | 11 | 82 (71 to 90) | — | — | — | 76 (64 to 86) | — | — | — | ||
| Test results negative | 12 | 179 | — | 91 (86 to 95) | — | — | — | 95 (91 to 97) | — | — | ||
| Test results inconclusive | 4 | 16 | — | — | 77 (65 to 86) | 94 (89 to 97) | — | — | 82 (70 to 91) | 92 (88 to 96) | ||
| CTA+MRI/MRA+DSA (n=151): | ||||||||||||
| Test results positive | 99 | 0 | 99 (95 to 100) | — | — | — | NA | — | — | — | ||
| Test results negative | 1§ | 51 | — | 100 (93 to 100) | — | — | — | NA | — | — | ||
| Test results inconclusive | 0 | 0 | — | — | 100 (96 to 100) | 98 (90 to 100) | — | — | NA | NA | ||
PPV=positive predictive value; NPV=negative predictive value; NA=not applicable.
*Reference standard was best available evidence from all findings during follow-up.
†Inconclusive result regarded as positive outcome.
‡Inconclusive result regarded as negative outcome.
§Underlying cavernoma was identified by repeated MRI 10 months after ictus.